ENTRY       D02597                      Drug
NAME        Adalimumab (USAN/INN);
            Adalimumab (genetical recombination) (JAN);
            Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN);
            Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN);
            Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN);
            Adalimumab (genetical recombination) [Adalimumab biosimilar 4] (JAN);
            Adalimumab-adaz;
            Adalimumab-adbm;
            Adalimumab-afzb;
            Adalimumab-atto;
            Adalimumab-bwwd;
            Adalimumab-fkjp;
            Humira (TN);
            Abrilada (TN);
            Amjevita (TN);
            Cyltezo (TN);
            Hadlima (TN);
            Hyrimoz (TN)
PRODUCT     ADALIMUMAB (Golden State Medical Supply)
            ADALIMUMAB (Mylan Specialty L.P.)
            ADALIMUMAB (Sandoz)
            ADALIMUMAB-ADBM (Boehringer Ingelheim Pharmaceuticals)
            AMJEVITA (A-S Medication Solutions)
            AMJEVITA (A-S Medication Solutions)
            AMJEVITA (Amgen USA)
            AMJEVITA (Amgen)
            CYLTEZO (Boehringer Ingelheim Pharmaceuticals)
            HADLIMA (A-S Medication Solutions)
            HADLIMA (A-S Medication Solutions)
            HADLIMA (A-S Medication Solutions)
            HADLIMA (Organon LLC)
            HULIO (Mylan Specialty L.P.)
            HUMIRA (A-S Medication Solutions)
            HUMIRA (AbbVie)
            HYRIMOZ (Cordavis Limited)
            HYRIMOZ (Sandoz)
            IDACIO (Fresenius Kabi USA)
            YUFLYMA (CELLTRION USA)
            YUSIMRY (Coherus BioSciences)
CLASS       Anti-inflammatory
             DG01985  Disease modifying anti-rheumatic drug (DMARD)
              DG01936  TNF inhibitor
REMARK      Therapeutic category: 3999
            ATC code: L04AB04
            Product: D02597<JP/US>
EFFICACY    Anti-inflammatory, Antirheumatic, Anti-TNF-alpha antibody
  DISEASE   Rheumatoid arthritis [DS:H00630]
            Juvenile idiopathic arthritis [DS:H01672]
            Psoriatic arthritis [DS:H01507]
            Ankylosing spondylitis [DS:H01674]
            Adult Crohn's disease [DS:H00286]
            Pediatric Crohn's disease [DS:H00286]
            Ulcerative colitis [DS:H01466]
            Plaque psoriasis [DS:H01656]
            Hidradenitis suppurativa [DS:H00681]
  TYPE      Monoclonal antibody
TARGET      TNF (TNFA, TNFSF2) [HSA:7124] [KO:K03156]
  PATHWAY   hsa04010(7124)  MAPK signaling pathway
            hsa04060(7124)  Cytokine-cytokine receptor interaction
            hsa04210(7124)  Apoptosis
            hsa04350(7124)  TGF-beta signaling pathway
            hsa04380(7124)  Osteoclast differentiation
            hsa04612(7124)  Antigen processing and presentation
            hsa04650(7124)  Natural killer cell mediated cytotoxicity
            hsa05321(7124)  Inflammatory bowel disease
            hsa05323(7124)  Rheumatoid arthritis
INTERACTION  
STR_MAP     map07050  Antirheumatics - DMARDs and biological agents
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
              L04 IMMUNOSUPPRESSANTS
               L04A IMMUNOSUPPRESSANTS
                L04AB Tumor necrosis factor alpha (TNF-alpha) inhibitors
                 L04AB04 Adalimumab
                  D02597  Adalimumab (USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Immunological Agents
              Immunosuppressants
               Tumor Necrosis Factor (TNF) Blockers
                Adalimumab
                 D02597  Adalimumab (USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             3  Agents affecting metabolism
              39  Other agents affecting metabolism
               399  Miscellaneous
                3999  Others
                 D02597  Adalimumab (USAN/INN); Adalimumab (genetical recombination) (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 1] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 2] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 3] (JAN); Adalimumab (genetical recombination) [Adalimumab biosimilar 4] (JAN)
            Drug groups [BR:br08330]
             Anti-inflammatory
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               DG01936  TNF inhibitor
                D02597  Adalimumab
            Drug classes [BR:br08332]
             Immunological agent
              DG01936  TNF inhibitor
               D02597  Adalimumab
             Antirheumatic agent
              DG01985  Disease modifying anti-rheumatic drug (DMARD)
               D02597  Adalimumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokines
               Tumor necrosis factors
                TNF (TNFA, TNFSF2)
                 D02597  Adalimumab (USAN/INN) &lt;JP/US&gt;
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D02597
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D02597
DBLINKS     CAS: 331731-18-1
            PubChem: 47205810
            NIKKAJI: J2.104.916F
///
